Coumadin — Competitive Intelligence Brief

Coumadin (warfarin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin K antagonist (anticoagulant). Area: Cardiovascular.

marketed Vitamin K antagonist (anticoagulant) Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7 Cardiovascular Small molecule

Target snapshot

Coumadin (warfarin) — Generic (originally Wisconsin Alumni Research Foundation). Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Coumadin TARGET	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01
Warfarin duration	Warfarin duration	British Thoracic Society	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin K antagonist (anticoagulant) class)

1. British Thoracic Society · 1 drug in this class
2. Generic (originally Wisconsin Alumni Research Foundation) · 1 drug in this class